Michelle Le Beau,PhD- Elected to ACS Board of Directors

The American Cancer Society has named Michelle M. Le Beau, PhD, director of the University of Chicago Medicine Comprehensive Cancer Center, to its board of directors, with a term beginning on Jan. 1, 2019.

Directors are elected for a two-year term. The all-volunteer board is responsible for setting policy, establishing long-term goals, monitoring general operations, and approving the organizational outcomes and allocation of resources.

“I am honored to join the board of the American Cancer Society – a key partner in the global fight against cancer,” said Le Beau. “I look forward to working with ACS leadership on our shared mission of supporting innovative, practice-changing cancer research, preventing cancer, and improving the quality-of-life of those facing cancer.”

In addition to her role as the director of a National Cancer Institute-designated Comprehensive Cancer Center, Le Beau is the Arthur and Marian Edelstein Professor of Medicine and director of the Cancer Cytogenetics Laboratory at the University of Chicago. She is board-certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics. She is also a member of the National Cancer Policy Forum of the National Academy of Medicine.

More : https://www.uchicagomedicine.org/forefront/cancer-articles/2018/december/michelle-m-le-beau-elected-to-the-american-cancer-society-board-of-directors


Originally published in The Forefront